CEO Guide for AI in Pharma
The Decision Desk · CEO Guide · AI in Pharma · September 2026 Edition
Ten Decisions
From AI Activityto AI Advantage.
Ten choices on capital, use cases, people, IP and governance that determine whether AI creates measurable advantage in Pharma, not just measurable activity.
Takes 30 seconds. No spam, just The Decision Desk, weekly.
What's inside the guide
01Posture: how aggressively should we move?
02Capital: where should we place our AI bets?
03Work: automate, augment or reinvent?
04People: what does AI mean for our workforce?
05Proprietary: what must remain ours?
06Technology: what should we actually own?
07Data: how much data work is really necessary?
08Governance: move fast without losing control
09Value: how do we know it is working?
10Agenda: the next 12 months
10 CEO-level questions
From capital allocation to workforce redesign to governance.
Built on primary research
Bain, McKinsey, Deloitte, BCG and EY, 2024 to 2026.
A 12-month agenda
Six concrete moves you can start this quarter.
“
Only 5% of surveyed life-sciences organizations describe gen AI as a consistent competitive differentiator, despite universal experimentation.
McKinsey, 2025 · cited in the guidePart of a 5-week series · Week 1 of 5
This is Week 1 of DecisionX's September series on Decision AI in Pharma, covering the CEO agenda, Commercial Excellence, Manufacturing Excellence, R&D Excellence, and a closing case study on what this actually returns.
The Decision Desk · CEO Guide
CEO Guide for AI in Pharma
Ten decisions. One download. Free, no spam, no sales pitch first.
Backed by Bain, McKinsey, Deloitte, BCG and EY research